ERBB2 and breast cancer: The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab.<h4>Conclusions</h4>In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer.